Currently, two vaccine candidates are entering efficacy trials in humans: ChAd3-ZEBOV, developed by GlaxoSmithKline (GSK), in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID) and rVSV-ZEBOV, developed by NewLink Genetics and Merck Vaccines USA, in collaboration with the Public Health Agency of Canada. Both have been shown to be safe and well tolerated in humans in Phase I clinical trials.